Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Precision BioSciences, Inc. (DTIL) is a clinical-stage biotechnology company focused on developing gene editing–based therapies using its proprietary ARCUS genome editing platform. The company operates within the biotechnology and genetic medicine industries, with activities spanning gene therapy, cell therapy, and in vivo genome editing. Its core objective is to enable precise, efficient, and scalable genome modifications for the treatment of serious diseases.
The company’s primary value proposition is its ARCUS nuclease technology, a distinct gene editing system derived from a naturally occurring homing endonuclease. Precision BioSciences was founded in 2006 and evolved from an early focus on gene editing research into a clinical-stage developer with multiple therapeutic programs and strategic collaborations. Over time, the company has shifted toward a partnership-driven model, prioritizing capital efficiency and selective internal development.
Business Operations
Precision BioSciences generates value primarily through research and development of gene editing therapies and through collaboration and licensing agreements with larger biopharmaceutical partners. Its operations are organized around therapeutic development programs in gene therapy, CAR T cell therapy, and in vivo genome editing, with revenue historically derived from collaboration payments, upfront license fees, and research funding rather than product sales.
The company controls its proprietary ARCUS genome editing platform, associated intellectual property, and manufacturing know-how for clinical-grade gene editing components. Precision BioSciences has entered into strategic collaborations and licensing arrangements with multiple partners, including pharmaceutical and biotechnology companies, to advance ARCUS-based programs while sharing development costs and risks. Its operating footprint is primarily research-focused, with clinical development activities conducted through third-party manufacturers and clinical research organizations.
Strategic Position & Investments
Precision BioSciences’ strategy emphasizes out-licensing and co-development partnerships to advance its technology while conserving capital. The company has executed several restructuring initiatives to focus resources on its most promising assets and partnered programs, reflecting a disciplined approach to portfolio management. Key strategic priorities include advancing ARCUS-enabled therapies into the clinic and monetizing the platform through partnerships.
Notable strategic actions have included licensing agreements and asset sales involving ARCUS-based programs, as well as investments in manufacturing and platform improvements to enhance editing precision and safety. The company maintains a selective internal pipeline while leveraging partners to pursue broader clinical and commercial opportunities, particularly in rare diseases and oncology.
Geographic Footprint
Precision BioSciences is headquartered in Durham, North Carolina, United States, and its operations are primarily based in North America. Research, corporate leadership, and administrative functions are centralized at its U.S. headquarters, supporting its platform development and clinical strategy.
While the company does not maintain extensive international facilities, its global footprint is extended through international clinical trials, global licensing partners, and collaborations with multinational biopharmaceutical companies. These partnerships provide Precision BioSciences with indirect exposure to Europe, Asia, and other international markets without maintaining a large direct operational presence abroad.
Leadership & Governance
Precision BioSciences is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and capital markets. The leadership emphasizes scientific rigor, capital discipline, and strategic partnerships as core elements of the company’s operating philosophy.
Key executives include:
- Michael Amoroso – President and Chief Executive Officer
- Jef Boeke – Chief Financial Officer
- Matthew Kane – Chief Operating Officer
- Deborah O’Brien – Chief Legal Officer and Corporate Secretary
- Tina Woolston – Chief Human Resources Officer
The board and executive team collectively guide corporate strategy, oversee risk management, and support long-term value creation through platform advancement and partnership-driven growth.